top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Kadimastem Announces Leadership Changes
NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef...
May 20, 20192 min read
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
Ness Ziona, Israel, April 18th 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval from the MOH of...
Apr 18, 20192 min read
Appointment of a new CFO for Kadimastem
The Current CFO has accepted a position as the Director of the Budget Division of the Jewish Agency for Israel Ness Ziona, Israel, 3...
Mar 3, 20191 min read
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
Ness Ziona, Israel, 24 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of cell...
Feb 24, 20192 min read
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
Ness Ziona, Israel, 17 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announces it has received approval for its...
Feb 17, 20191 min read
Kadimastem to be included in the TASE Indices
Ness Ziona, Israel, November 27, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) received an announcement from the TASE, that...
Nov 27, 20181 min read
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise...
Nov 14, 20181 min read
Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the approval by the European Union...
Nov 12, 20182 min read
FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS
The FDA grants orphan drug status to incentivize the development of one of a kind drugs and other medical treatments. This status grants...
Nov 4, 20182 min read
Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:
Ness Ziona, Israel, October 9, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces progress in the Phase 1 / 2a...
Oct 9, 20183 min read
Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem
Ness Ziona Science Park, Israel, October 2, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of...
Oct 2, 20182 min read
Kadimastem and The AFDR Selected to Receive a bi-National Grant
Ness Ziona, Israel, July 2nd 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval of the Australian...
Jul 2, 20182 min read
Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial
Kadimastem chose to upgrade the production rooms, for the treatment of ALS patients in the Phase 1 / 2a clinical trial, and adapt them to...
Jul 1, 20181 min read
Kadimastem was honored with a prize for excellence for the presentation of the company's technology
Between June 20 and 22, 2018, European conference was held for ALS (ENCALS) at Oxford University in England. During the conference, the...
Jun 27, 20181 min read
Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:
Report in English and a Hebrew summary https://maya.tase.co.il/reports/details/1167249/2/0 https://maya.tase.co.il/reports/details/116724...
Jun 13, 20181 min read
Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published
Jun. 6, 2018 by a Prestigious Cell Therapy Scientific Journal Ness Ziona, Israel, 6 June 2018, Israeli biotechnology company Kadimastem...
Jun 6, 20183 min read
Successful Public Offering for Kadimastem
May. 15, 2018 Ness Ziona, Israel, May 15, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the completion of a...
May 15, 20181 min read
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
Apr. 26, 2018 Ness Ziona, Israel, 26 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the enrollment of...
Apr 26, 20182 min read
Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes
Ness Ziona, Israel, 22 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the signing of a memorandum of...
Apr 21, 20183 min read
Successful Rights Offering for Kadimastem; Raised NIS 5.1M
The company's stakeholders invested a substantial sum of NIS 3.8M Ness Ziona, Israel, 13 November 2014, Israeli biotechnology company...
Nov 13, 20141 min read
bottom of page